Lesson plan
TM-38837
TM-38837 is a small molecule inverse agonist/antagonist of the CB 1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials. TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB 1 receptor antagonists such as rimonabant. The structure of TM-38837 has been erronously referred to in the past as compound 8 in reference but is now known from a more recent reference.
Article summary
TM-38837 is a small molecule inverse agonist/antagonist of the CB 1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials. TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB 1 receptor antagonists such as rimonabant. The structure of TM-38837 has been erronously referred to in the past as compound 8 in reference but is now known from a more recent reference.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.